Cargando…
IDegLira improves patient‐reported outcomes while using a simple regimen with fewer injections and dose adjustments compared with basal–bolus therapy
AIMS: Basal–bolus therapy is associated with greater treatment burden and lower adherence compared with more simplified regimens. This post hoc analysis studied the difference between insulin degludec/liraglutide (IDegLira) and basal–bolus therapy on number of injections, dose adjustments and patien...
Autores principales: | Miller, Eden, Doshi, Ankur, Grøn, Randi, Jódar, Esteban, Őrsy, Petra, Ranthe, Mattis F., Sugimoto, Danny, Tentolouris, Nikolaos, Viljoen, Adie, Billings, Liana K. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Blackwell Publishing Ltd
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6899651/ https://www.ncbi.nlm.nih.gov/pubmed/31385425 http://dx.doi.org/10.1111/dom.13851 |
Ejemplares similares
-
IDegLira Improves Glycemic Control in Japanese Patients with Uncontrolled Type 2 Diabetes on Premixed Insulin Therapy
por: Watada, Hirotaka, et al.
Publicado: (2019) -
Evaluation of the Short-Term Cost-Effectiveness of IDegLira Versus Basal Insulin and Basal-Bolus Therapy in Patients with Type 2 Diabetes Based on Attainment of Clinically Relevant Treatment Targets
por: Cannon, Anthony J., et al.
Publicado: (2020) -
Persistence with IDegLira in Patients in Clinical Practice: A Nationwide Observational Study in Sweden
por: Eliasson, Björn, et al.
Publicado: (2020) -
Insulin degludec/liraglutide (IDegLira) was effective across a range of dysglycaemia and body mass index categories in the DUAL V randomized trial
por: Lingvay, Ildiko, et al.
Publicado: (2017) -
Insulin degludec/liraglutide (IDegLira) maintains glycaemic control and improves clinical outcomes, regardless of pre‐trial insulin dose, in people with type 2 diabetes that is uncontrolled on basal insulin
por: Meneghini, L., et al.
Publicado: (2019)